Announcements - OBI Pharma 台灣浩鼎

2022.Nov.04

Announcement of the Consolidated Financial Statements for the third quarter of 2022 were approved by the Board of Directors

2022.Oct.25

The Chairman decided the record date of 2022 first issuance of RSU according to the resolution Of BOD

2022.Oct.18

Announcement on behalf of AP Biosciences that the BOD resolved to convene 2022 first extraordinary General Shareholders' Meeting

2022.Oct.13

OBI-822 “Cancer Immunotherapy by Immune Activation or Immune Modulation via Globo Series Antigens“ was granted by USPTO

2022.Oct.06

Announcement on behalf of AP Biosciences of the resignation of its institutional director

2022.Oct.05

OBI PHARMA INC. to attend investor conference hosted by MASTERLINK SECURITIES

2022.Oct.04

Announcement of AP Biosciences’ full receipt of cash capital increase in 2022 and the reference date of capital increase

2022.Oct.03

Announcement of the expiration of AP Biosciences’ 2022 cash capital increase call period

2022.Sep.12

Announcement on behalf of AP Biosciences to file application for Phase I human clinical trial of Bispecific Antibody, AP203, to TFDA

2022.Sep.10

Announcement on behalf of AP Biosciences that application for Phase I human clinical trial of Bispecific Antibody, AP203, has been granted by US FDA

News

Latest News

Events

Latest events